The Clinical Relevance of Tumor Biomarkers in Prostate Cancer-A Review.
1/5 보강
Prostate cancer is one of the most common malignancies in men worldwide.
APA
Majewska Z, Zajkowska M, et al. (2025). The Clinical Relevance of Tumor Biomarkers in Prostate Cancer-A Review.. Cancers, 17(23). https://doi.org/10.3390/cancers17233742
MLA
Majewska Z, et al.. "The Clinical Relevance of Tumor Biomarkers in Prostate Cancer-A Review.." Cancers, vol. 17, no. 23, 2025.
PMID
41374944 ↗
Abstract 한글 요약
Prostate cancer is one of the most common malignancies in men worldwide. Therefore, there is an urgent need to develop accurate, accessible biomarkers for diagnosis, prognosis, and therapy monitoring. Tumor markers, which can be measured in blood, urine, or tissue, provide valuable information regarding tumor presence, progression, and response to treatment. This review provides a comprehensive overview of routinely used diagnostic and emerging biomarkers for prostate cancer, based on a systematic MEDLINE/PubMed search. Key biomarkers analyzed include PSA and its derivatives, PCA3, and TMPRSS2-ERG, as well as genomic tests such as Prolaris, Decipher, and ConfirmMDx, and liquid biopsy-based tests such as ExoDx Prostate and SelectMDx. This narrative review demonstrates that although PSA remains the mainstay of prostate cancer diagnosis, emerging molecular and genomic biomarkers are enhancing diagnostic specificity, refining risk stratification, and enabling more personalized patient care. The integration of routinely used and novel biomarkers can improve early detection, optimize treatment decisions, and ultimately improve outcomes of prostate cancer patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- FOXA1 Alterations in Prostate Cancer: Expression, Mutation Classes, and Copy Number Changes.
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.
- Prostate cancer associated 3 (PCA3) is a potential indicator of the pathological grades of prostate cancer.
- Affordable ultrasensitive electrochemical detection of PCA3 for early prostate cancer diagnosis.
- Combination of prostate cancer antigen 3 (PCA3), sarcosine, glypican-1 (GPC1), urokinase plasminogen activator receptor (uPAR), and thymidine kinase 1 (TK1), and T2WI and DWI radiomics model for distinguishing benign prostatic hyperplasia, prostate cancer, and prostatitis.
- Evaluation of LncRNAs CBR3-AS1 and PCA3 expression in Gastric cancer and their correlation to clinicopathological variables.